Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer

PURPOSE: How to factor both tumor burden and oncogenic genomic mutations as variables to predict the outcome of endocrine-based therapy (ET) in ER-positive/HER2-negative metastatic breast cancer patients (MBC) remains to be explored. METHOD: Blood samples prospectively collected from 163 ER-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tom Wei-Wu, Hsiao, Wen, Dai, Ming-Shen, Lin, Ching-Hung, Chang, Dwan-Ying, Chen, I-Chun, Wang, Ming-Yang, Chang, Shu-Han, Huang, Shu-Min, Cheng, Ann-Lii, Wu, Ko-Wen, Tan, Kien Thiam, Lu, Yen-Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460702/
https://www.ncbi.nlm.nih.gov/pubmed/37344660
http://dx.doi.org/10.1007/s10549-023-06967-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460702/
https://www.ncbi.nlm.nih.gov/pubmed/37344660
http://dx.doi.org/10.1007/s10549-023-06967-3

Ejemplares similares